Longitudinal model–based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer

被引：0
|
作者：
Wenjun Chen
Liang Li
Shuangmin Ji
Xuyang Song
Wei Lu
Tianyan Zhou
机构：
[1] Peking University,Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, Department of Pharmaceutics, School of Pharmaceutical Sciences
[2] National Medical Products Administration,Center for Drug Evaluation
[3] University of Florida,Department of Pharmaceutics, College of Pharmacy
来源：
European Journal of Clinical Pharmacology | 2020年 / 76卷
关键词：
Model-based meta-analysis; Castration-resistant prostate cancer; Progression-free survival; Overall survival; Longitudinal data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：589 / 601
页数：12
相关论文
共 50 条
  • [11] Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis
    Qin, Zhiqiang
    Li, Xiao
    Zhang, Jianzhong
    Tang, Jingyuan
    Han, Peng
    Xu, Zhen
    Yu, Yajie
    Yang, Chengdi
    Wang, Chengming
    Xu, Ting
    Xu, Zicheng
    Zou, Qing
    MEDICINE, 2016, 95 (39)
  • [12] A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
    Alameddine, Zakaria
    Niazi, Muhammad Rafay Khan
    Rajavel, Anisha
    Behgal, Jai
    Keesari, Praneeth Reddy
    Araji, Ghada
    Mustafa, Ahmad
    Wei, Chapman
    Jahangir, Abdullah
    Terjanian, Terenig O.
    CURRENT ONCOLOGY, 2023, 30 (10) : 9262 - 9275
  • [13] Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials
    Tunio, Mutahir
    Al Asiri, Mushabbab
    Al Hadab, Abdulrehman
    Bayoumi, Yasser
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5291 - 5299
  • [14] Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer
    Yamasaki, Mutsushi
    Yuasa, Takeshi
    Yamamoto, Shinya
    Hayashi, Tatsuro
    Ogawa, Masahiro
    Sakura, Mizuaki
    Masuda, Hitoshi
    Fukui, Iwao
    Yonese, Junji
    ANTICANCER RESEARCH, 2016, 36 (01) : 361 - 365
  • [15] Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
    von Eyben, Finn Edler
    Bauman, Glenn
    von Eyben, Rie
    Rahbar, Kambiz
    Soydal, Cigdem
    Haug, Alexander R.
    Virgolini, Irene
    Kulkarni, Harshad
    Baum, Richard
    Paganelli, Giovanni
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 17
  • [16] Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer A protocol of systematic review and meta-analysis
    Pu, Chun-Lin
    Li, Jiu-Zhi
    Fan, Wen-Long
    MEDICINE, 2020, 99 (21) : E20297
  • [17] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [18] Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization
    Al-Ali, Badereddin Mohamad
    Kramer, Gero
    Madersbacher, Stephan
    Berger, Ingrid
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (11-12) : 380 - 384
  • [19] Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
    Niazi, Muhammad Rafay Khan
    Jahangir, Abdullah
    Sahra, Syeda
    Sattar, Saud Bin Abdul
    Asti, Divya
    Bershadskiy, Alexander
    ONCOLOGY-NEW YORK, 2021, 35 (11): : 708 - 715
  • [20] Apalutamide for the treatment of patients with castration-resistant prostate cancer
    Hauke, R.
    DRUGS OF TODAY, 2018, 54 (10) : 585 - 590
12345